The FDA has approved selexipag for IV use in adults with WHO functional class II to III pulmonary arterial hypertension who are temporarily unable to take oral therapy. Selexipag (Uptravi, Janssen) for IV use will allow patients to avoid short-term interruptions and stay on their therapy, as uninterrupted treatment is important for patients with PAH, according to a company press release.
Patient care technician staffing at U.S. dialysis facilities varies by geography, time and other attributes, data show. Further investigation could lead to better quality of…
The Mine Safety and Health Administration within the U.S. Department of Labor has finalized stricter limits on silica dust exposure for miners, according to a…
Compared with healthy individuals, having undiagnosed COPD or asthma negatively impacted quality of life and led to higher health care usage, according to results published…
More than 1,600 health care professionals celebrated the approval of Rezdiffra, the first treatment for adults with metabolic dysfunction-associated steatohepatitis, according to a global online…
BOSTON — Most people in the United States do not get enough vitamin D, but supplementation helps patients reach the daily recommended dietary allowance, according…
In this Healio Video Perspective from the ASCRS meeting, John D. Sheppard, MD, MMSc, FACS, discusses a post hoc analysis of two clinical trials investigating…
Among patients with chronic coronary syndrome, women were less likely than men to be treated with lipid-lowering therapy, researchers reported at ESC Preventive Cardiology 2024.Women…
Decades of declining heart failure mortality in the U.S. has reversed, and exceeded rates recorded more than 20 years ago, according to overall population-level data…
Few areas in cardiology are as active as development and implementation of medical therapies for heart failure, and few people are as familiar with that…
HOUSTON — Peter J. Hotez, MD, PhD, has been working in vaccine development for more than 40 years.
